NCT03866343

Brief Summary

Current efforts to arrest the epidemic of type 2 diabetes mellitus (T2DM) have had limited success. Thus there is an urgent need for effective approaches to prevent the development of T2DM. It is widely accepted that the current epidemic is driven by an increase in global food abundance and reduced food quality, making changes in diet a key determinant of the T2DM epidemic. Dietary factors can affect cardio-metabolic health; among these factors, advanced glycation end-products (AGEs) in food are potential risk factors for insulin resistance and T2DM. AGEs are a heterogeneous group of unavoidable stable bioactive compounds. Endogenous formation of AGEs is a continuous naturally occurring process, and is the result of normal metabolism. However, increased formation of AGEs occurs during ageing and under hyperglycaemic conditions. AGEs are implicated in the development of diabetes and vascular complications. Over the past several decades, methods of food processing have changed and meals now contain excess fat and sugar and are most susceptible for the formation of AGEs. In addition, AGEs in food are highly desirable due to their profound effect on shelf life, sterility, flavour, colour, and thus food consumption. Hence, a substantial portion of AGEs are derived from exogenous sources, particularly food. These exogenous AGEs are potential risk factors for insulin resistance and the development of T2DM. The investigators recently found that dietary AGEs represent a significant source of circulating AGEs, and have similar pathogenic properties compared to their endogenous counterparts including the development of insulin resistance and T2DM. Taken together, dietary AGEs are proposed to play a pivotal role in the development and progression of T2DM and its complications. Reduction of dietary intake of AGEs may therefore be an alternative strategy to reduce the risk of vascular disease and insulin resistance. The investigators therefore hypothesize that dietary restriction of AGEs in overweight individuals improves insulin sensitivity, β-cell function, and vascular function.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 7, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 6, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 7, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2021

Completed
Last Updated

March 8, 2021

Status Verified

March 1, 2021

Enrollment Period

2.5 years

First QC Date

March 6, 2019

Last Update Submit

March 5, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Insulin sensitivity

    Assessed by hyperinsulinaemic-euglycaemic clamp

    Difference after 4 weeks of intervention

Secondary Outcomes (1)

  • Microvascular function

    Difference after 4 weeks of intervention

Study Arms (2)

Low AGE diet

ACTIVE COMPARATOR

Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.

Other: Diet low or high in advanced glycation endproducts

High AGE diet

OTHER

Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.

Other: Diet low or high in advanced glycation endproducts

Interventions

All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.

High AGE dietLow AGE diet

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Abdominal obesity: waist circumference for men ≥ 102 cm, and for women ≥ 88 cm.
  • Aged 18 years and older
  • Caucasian (because of skin fluorescence and capillary microscopy measurements)

You may not qualify if:

  • Diabetes (i.e. using anti-diabetic medication, fasting glucose \>7.0 mmol/L, HbA1c \>6.5%).
  • Active or history of cardiovascular disease (e.g. stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
  • Hyperlipidemia (defined as serum total cholesterol \> 8 mmol/L or TG \> 4 mmol/L)
  • Lipid lowering medication (e.g. statins)
  • Use of medication known to influence glucose metabolism, vascular function and/or lipid metabolism (e.g. statins, glucocorticosteroids, NSAID's)
  • Pulmonary or inflammatory disease
  • Kidney failure or electrolyte disorders
  • Pregnancy or lactation
  • No change in use of oral anticonceptiva or IUD (12 weeks prior of during the intervention)
  • Known allergic reaction to ultrasound contrast-agent
  • Smoking (active or cessation \<1 year prior to screening date).
  • High alcohol usage (\>4 U/day) or drug abuse
  • Use of dietary supplements or an investigation product within the previous month
  • Significant food allergies/intolerance
  • Vegetarianism
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University

Maastricht, Limburg, 6226, Netherlands

Location

Related Publications (1)

  • Linkens AM, Houben AJ, Niessen PM, Wijckmans NE, de Goei EE, Van den Eynde MD, Scheijen JL, van den Waarenburg MP, Mari A, Berendschot TT, Streese L, Hanssen H, van Dongen MC, van Gool CC, Stehouwer CD, Eussen SJ, Schalkwijk CG. A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. JCI Insight. 2022 Mar 22;7(6):e156950. doi: 10.1172/jci.insight.156950.

MeSH Terms

Conditions

Insulin Resistance

Interventions

Glycation End Products, Advanced

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

GlycoconjugatesCarbohydratesToxins, BiologicalBiological Factors

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2019

First Posted

March 7, 2019

Study Start

September 7, 2018

Primary Completion

March 3, 2021

Study Completion

March 3, 2021

Last Updated

March 8, 2021

Record last verified: 2021-03

Locations